Chapter 1
From DMSO to the Anticancer Compound SAHA, an Unusual Intellectual Pathway for Drug Design

Ronald Breslow

1.1
Introduction

This is an account of aspects of a collaboration between Ronald Breslow (originally Professor of Chemistry at Columbia University, also a member of the Biological Sciences Department, now University Professor at Columbia) and Paul Marks (originally Professor of Human Genetics and Medicine, Dean of the Faculty of Medicine, then Vice President for Health Sciences and Director of the Comprehensive Cancer Center at Columbia University, then President and Chief Executive Officer at Memorial Sloan Kettering Cancer Center, now President Emeritus and Member of the Sloan Kettering Institute) in the invention and development of suberoylanilide hydroxamic acid (SAHA), an effective anticancer agent that has been in human use for years after approval in the United States, Canada and more recently Japan. The Breslow group designed new potential molecules and carried out their syntheses in the Columbia University chemistry department, and submitted them to Paul Marks and Richard Rifkind at the Columbia Cancer Center, and later at the Sloan Kettering Institute for Cancer Research, for biological evaluation. Paul Marks instituted the collaboration, based on some work by Charlotte Friend of Mount Sinai School of Medicine.

This is the way most modern pharmaceuticals are created in pharmaceutical companies or in academic medicinal departments. Biologists may be aware of a promising area for drug development, medicinal chemists then design and create candidate molecules and send them to the biologists, who then evaluate them. With promising results, the chemists continue to create new, perhaps better, candidates while the biologists extend testing to animals and then to humans. Successful medicines are then approved for human use.

Normally the chemists are aware of compounds that have some promise, based on binding studies, and they can design around those structures. In the case of SAHA, the initial lead, dimethylsulfoxide (DMSO) **1**, was very far from a potential medicine so the design was based on a series of hypotheses. Even so, the eventual structure of SAHA proved to be ideal as a binder to the biological target, although this is not how it was discovered. Thus the editors of this volume have invited

me to describe the unusual intellectual history that led to its structure. I am a physical organic chemist who had designed and created new molecules for novel properties, such as unusual conjugative stability or instability, or effective catalytic enzyme mimics, but not medicinal properties. However, I have a Master's degree in Medical Science from Harvard University in addition to my Ph.D. in Chemistry, and I had been a consultant with pharmaceutical companies for many years. There I proposed both new synthetic approaches to their target compounds and also possible alternative medicinal targets themselves.

A few years ago, Paul Marks and I wrote a short review describing the work of both our labs in the development of SAHA [1], but the present chapter will concentrate only on the chemical approach that led to drug development. Thus it does not describe in detail the brilliant biological work done by Paul Marks and Richard Rifkind. The references are only those in which Paul Marks and I are both authors, and it will not cover the many papers and a book produced by the Marks lab alone and several papers from only our lab that related the SAHA story to our other work.

1.2
The Discovery of SAHA (vorinostat)

Stem cells have two functions. They multiply to form additional stem cells, and they differentiate to adult tissue cells with specialised functions. In 1966 Paul Marks approached me with the information that Charlotte Friend had seen something remarkable [2, 3]. When a suspension of murine erythroleukemia cells (MELC) was treated with dimethylsulfoxide (DMSO) (**1**) at 280 mmolar approximately 60% of the cells underwent cytodifferentiation to normal erythrocytes. This was the first example in which such a process occurred, and it suggested a new approach to cancer treatment generally. Of course such a required concentration was totally impractical for a medicine, so it was important to find more potent analogs of DMSO. Marks and I agreed to collaborate and build a research programme based on this finding. The Breslow lab with my students and postdocs would conceive and create new compounds that would be tested by Marks and his associates for cytodifferentiation of erythroleukemia cells, as DMSO had done, but with more practical doses. Marks would also further evaluate promising leads with biological testing. This led to the discovery of SAHA. In time Marks and Breslow and Richard Rifkind formed a company, ATON Pharma Inc. It received the patent rights from Columbia University and Sloan Kettering and funded the Phase I human trials for SAHA.

Many small molecule linear and cyclic amides were examined. *N*-Methylacetamide (**2**) was fivefold more effective than DMSO, but still not effective enough to be a practical drug [4]. Thus the chemists decided to create linked dimers of acetamide, to take advantage of the well-known chelate effect that leads to stronger binding, and thus should require lower doses for anticancer effectiveness. Double binders have entropy advantages over single ligands if both ends

Figure 1.1 **1** *N*-methylacetamide, **2** dimethylsulfoxide (DMSO), **3** hexamethylene bis-acetamide, **4** suberoyl-bis-*N*-methylamide.

contribute to the binding. This involved the hope that there were more binding sites than a single one for the initial compounds, and thus linking them together could be useful. The first compound, hexamethylene bis-acetamide (HMBA, linked at the nitrogen atoms) (**3**), was indeed one order of magnitude (tenfold) more potent than simple acetamide, and changing the linking groups from three methylenes up to nine made it clear that a six methylene chain – the first one we tried – was the optimum [5–7]. This preference will eventually be seen and understood when we describe SAHA. We also prepared a dimer of acetamide linked at the methyl groups, suberoyl-bis-*N*-methylamide (**4**), and it also showed tenfold stronger binding than simple acetamide [8]. Various dimers including dimers of DMSO were also examined [8, 9]. HMBA had extensive biological study, and indeed some human trials were performed with HMBA [10–13]. There were some useful responses in cancer patients, but the doses required were too high to be well tolerated in human patients. When even trimers and tetramers of acetamide were not more effective [14, 15], we concluded that simple amides were not bound strongly enough.

We were already thinking that the target could be an enzyme, perhaps a metalloenzyme, to explain the strong preference for particular lengths of our compounds. Since DMSO and the amides had polar groups that could be metal ligands, we decided to go to even better metal ion binders. We synthesised a bis-amide like **4** but with hydroxyl groups instead of methyl groups, creating compound **5** that we called suberoyl-bis-hydroxamic acid, SBHA [14]. Hydroxamic acids were known to be strong binders to metal ions. Compound **5** was more effective than was HMBA, compound **3**, suggesting that indeed there was a metal ion in the biological target. Again the six-methylene chain length was optimal. However, the chance that a receptor protein would have *two* metal ions that distance apart seemed unlikely, so we decided to replace the hydroxyl of one hydroxamic group with a hydrophobic phenyl group to see if it could make an even better binder. This would bind to a metal ion with its hydroxamic group while binding to a hydrophobic region of a protein with the phenyl group. This was speculation, but it turned out to be correct.

Figure 1.2 **5** suberyol-bis-hydroxamic acid (SBHA), **6** suberyolanilide hydroxamic acid (SAHA).

We created SAHA, suberoylanilide hydroxamic acid **6** [14]. It inhibited histone deacetylases was approximately sixfold more potent than was SBHA in the MELC assay and also in various other tests [15–17]. Again we varied the chain length, and the six-methylene linker was optimal. We and others have replaced the phenyl group with many other larger hydrophobic units, which made compounds much more strongly bound, but in animal studies the more strongly bound analogs showed increased toxicity. This represents a fundamental problem not always recognised by medicinal chemists.

A binding constant is a ratio of two rate constants, the second-order rate constant for binding over the first-order rate constant for dissociation. It is often difficult to increase the rate of binding, which is limited by the collision rate. Strong binding instead often reflects slower dissociation, the first-order process, as the attractive interactions must be broken. Thus strong binders are often bound to biological receptors for a longer time. Putting it another way, for effectiveness a drug must normally be 50% or so bound to the receptor, and with strong binders a smaller dose is needed for 50% binding. If the strong binding reflects slower dissociation, the drug will be present on the biological targets for a long time. In the case of SAHA, physicians have found that unpleasant or dangerous side effects are minimised in human patients if the drug is present for only 8 h or so before excretion, so SAHA is administered once a day. With tenfold slower dissociation the drug would be present for 80 h, and side effects could be serious. With any SAHA analog significantly more strongly bound – and we looked at several with subnanomolar dissociation constants – adverse toxic side effects appeared in animal tests that could not be overcome by cutting back the dose.

SAHA proved to be an effective drug against a variety of cancers, as Paul Marks and our other collaborators established. In some cases the cancer cells differentiated into normal cells, as had happened with DMSO in the Charlotte Friend experiments. Examples included human colon (HT-29) and adult leukemia (HL-60) cells. The National Cancer Institute (NCI) then examined SAHA in sixty different human cancer cell types and saw stasis (lack of growth) with all, and about equal occurrences of either cytodifferention to normal cells or apoptosis (programmed cell death, not simple toxicity). SAHA also caused cytodifferention of MCF-7 breast adenocarcinoma cells into normal functioning breast milk cells. Very many cancers have been examined with SAHA.

The scientific question is, of course, how does SAHA cause these effects? A strong clue came from the work of Yoshida with two other cytodifferentiating agents, trichostatin A and trapoxin B. He showed that they induced cytodifferentiation by inhibiting the enzyme histone deacetylase (HDAC) [18]. The structure of trichostatin A **7** is similar to that of SAHA, although it is a less attractive drug. We saw that SAHA was also an inhibitor of HDAC and that the potency of various SAHA derivatives as HDAC inhibitors ran parallel to their biological anticancer effectiveness. We created a derivative **8** of SAHA with an azido group on the phenyl para position and tritium labeling in the phenyl, and irradiated it with HDAC in solution. The azido group lost nitrogen to form a reactive nitrene that then attached it to HDAC, so it was clear that HDAC was the binding tar-

get [19]. Finally, X-ray crystal structures were obtained in the lab of Pavletich that showed the detailed structure of the complex of SAHA and of trichostatin A with HDAC [20]. SAHA bound into HDAC by inserting into a pore with the phenyl group bound to a surface hydrophobic face of the protein while the hydroxamic acid group bound to a Zn^{2+} metal ion that was part of the HDAC protein. The six methylenes were the perfect length to reach between these two binding sites. We also synthesised a compound called pyroxamide **9** in which a pyridine ring replaced the phenyl ring of SAHA, and it had similar properties to SAHA [21].


7

(trichostatin A)

8

(*N*-(4-azidophenyl-3,5-*t*$_2$)-*N'*-hydroxy-octanediamide)

9

(pyroxamide)

Figure 1.3

The enzyme histone deacetylase binds an acetylated lysine from the protein histone at the zinc of HDAC, which catalyzes the hydrolysis of the acetyl group – hence histone deacetylase. The structure of SAHA bound to HDAC almost perfectly matches the structure of an acetylated lysine group of histone bound into the pore of the protein, with the six-methylene chain mimicking the side chain of an acetylated lysine. Although SAHA was not invented this way, it is ideal as a mimic of the transition state for zinc-catalyzed hydrolysis of an acetylated lysine group from histone. Other work not detailed here shows that particular lysines, when acetylated, can induce differentiation of stem cells or cancer cells, so blocking the deacetylation as SAHA does upregulate (increase) the acetylation level of the histone [22, 23]. Other studies suggest how apoptosis is also triggered by SAHA.

1.3
Clinical Trials

Phase I trials of SAHA in human cancer patients showed that it was well tolerated and that it had useful clinical results. At this point more extensive trials were needed, and several companies were interested in buying ATON for SAHA and its patents and data. Merck and Co bought ATON in 2004, and performed trials that were successful, so Merck obtained approval for the human use of SAHA against disease, first in the United States in 2006, then in Canada in 2009 and more

recently in 2011 in Japan. SAHA has been used in clinical trials against many cancers, and it is still in active use in chemotherapy treatment of cancer patients.

1.4
Follow-On Research – Selective HDAC Inhibitors

Humans have eleven different zinc-dependent HDACs, with different structures and different selectivities for the cleavage of acetyl groups from various proteins. SAHA has rather broad selectivity among them, but a particular enzyme called HDAC6 is selective for the removal of acetyl groups from the protein tubulin; it is less effective against acetylated histone, for example. Thus the name *histone* deacetylase (HDAC) is a misnomer, since some of these deacetylases have other protein targets. The first example of an inhibitor of HDAC6 was a compound called tubacin, created by Schreiber in 2003 [24]. Kozikowski has been studying enzymes with such selectivity, and has made some compounds that are selective in blocking hydrolytic removal of the acetyl group from acetylated tubulin. He has suggested that HDAC6 has a shorter distance from the surface of the protein to the hydroxamic acid site. We have two very promising compounds that are quite selective for HDAC6 alone among the HDACs. They were designed to have a shorter distance between the surface and the HDAC group than SAHA has, and both have a branching group that prevents the compound from penetrating further into the protein cavity.

One compound we called HPOB, **10**, selectively inhibits HDAC6 catalytic activity *in vivo* and *in vitro* [25]. Paul Marks compared it with Schreiber's tubacin and saw that HPOB was 51.8-fold selective for HDAC6 versus HDAC1 while tubacin was only 4.3-fold selective. As we described, HPOB has very good biological properties, and is very promising in combination therapy to enhance the potency of various anticancer drugs. A second compound we call HPB, **11**, we described in a paper just published in Proceedings of the National Academy of Sciences [26]. It is a little less selective than HPOB but it has even better anticancer properties, including lack of side effects, in animal studies. Both compounds need human evaluation before they can be seen as true improvements over SAHA. We are planning such studies.

Figure 1.4 *N*-hydroxy-4-[(*N*(2-hydroxyethyl)-2-phenylacetamido)-methyl)benzamide] (HPB), 4-[(hydroxyamino)carbonyl]-*N*-(2-hydrocyethyl)-*N*-phenyl-benzeneacetamide (HPOB).

1.5
Conclusion

It has been over 40 years since Charlotte Friend placed transfected MELC cells in the presence of DMSO and started the field down the path of using HDAC inhibition to treat cancer. Since the approval of vorinostat for the treatment of persistent cutaneous T-cell lymphoma in 2006 (currently marketed under the trade name Zolinza®), a number of HDAC inhibitors from multiple chemical classes have followed suit. Some of these are discussed in following chapters. I am told by medicinal chemistry colleagues from Memorial Sloan–Kettering Cancer Center who are actively engaged in cancer drug discovery that SAHA is still used by physicians and continues to be a useful medicine for the treatment of human cancers. All things considered, this is a gratifying destiny for a drug whose origins began with such a simple molecule as DMSO.

List of Abbreviations

AIDS   autoimmune deficiency syndrome
DMSO   dimethylsulfoxide
HDAC   histone deacetylase
HMBH   hexamethylene bis-acetamide
HPB   *N*-hydroxy-4-[(*N*(2-hydroxyethyl)-2-phenylacetamido)-methyl)-benzamide]
HPOB   4-[(hydroxyamino)carbonyl]-*N*-(2-hydroxyethyl)-*N*-phenyl-benzene-acetamide
MELC   murine erythroleukemia cells
PNAS   Proceedings of the National Academy of Sciences, USA
SAHA   suberoylanilide hydroxamic acid
SBHA   suberoyl-bis-hydroxamic acid

References

1 Marks, P.A. and Breslow, R. (2007) Dimethylsulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. *Nat. Biotechnol.*, **25**, 84–90.

2 Friend, C., Patuleia, M.C. and DeHarven, E. (1966) Erythrocytic maturation in vitro of virus-induced leukemic cells. Cells. *Natl. Cancer Inst. Monogr.*, **22**, 505–520.

3 Friend, C., Scher, W., Holland, J.G. and Sato, T. (1971) Hemoglobin synthesis in murine virus-induced leukemic cells *in vitro*: Stimulation of erythroid differentiation by dimethyl sulfoxide. *Proc. Natl. Acad. Sci. USA*, **68**, 378–382.

4 Tanaka, M., Levy, J., Terada, M., Breslow, R., Rifkind, R.A. and Marks, P.A. (1975) Induction of erythroid differentiation in murine virus infected erythroleukemia cells by highly polar compounds. *Proc. Natl. Acad. Sci. USA*, **72**, 1003–1006.

5 Reuben, R.C., Wife, R.L., Breslow, R., Rifkind, R.A., Marks, P.A. (1976) A new group of potent inducers of differentiation in murine erythroleukemia cells. *Proc. Natl. Acad. Sci. USA*, **73**, 862–866.

6 Reuben, R.C., Wife, R.L., Breslow, R., Rifkind, R.A. and Marks, P.A. (1976) Identification of a new group of potent inducers of differentiation in murine erythroleukemia cells. *Proc. Am. Assoc. Cancer Res.*, **17**, 76.

7 Marks, P.A., Reuben, R., Epner, E., Breslow, R., Cobb, W., Bogden, A.E. and Rifkind, R.A. (1978) Induction of murine erythroleukemia cells to differentiate: A model for the detection of new anti-tumor drugs. *Antibiot. Chemother. (Basel)*, **23**, 33.

8 Reuben, R.C., Khanna, P.L., Gazitt, Y., Breslow, R., Rifkind, R.A. and Marks, P.A. (1978) Inducers of erythroleukemic differentiation; relationship of structure to activity among planar–polar compounds. *J. Biol. Chem.*, **253**, 4214–4218.

9 Marks, P.A., Breslow, R., Rifkind, R.A., Ngo, L. and Singh, R. (1989) Polar/apolar chemical inducers of differentiation of transformed cells: Strategies to improve therapeutic potential. *Proc. Natl. Acad. Sci. USA*, **86**, 6358–6362.

10 Marks, P.A., Breslow, R. and Rifkind, R.A. (1989) Induced cytodifferentiation of transformed cells: An approach to cancer treatment. *J. Cell. Pharmacol.*, **262**, 7–11.

11 Marks, P.A., Rifkind, R.A. and Breslow, R. (1990) Induced differentiation of transformed cells: Mechanism of action and application in cancer therapy, in *Molecular Basis of Haematopoiesis*, (eds L. Sachs, N.G. Abraham, C. Weidemann, A.S. Levineand G. Konwalinka), Intercept, Ltd., Andover, pp. 579–586.

12 Breslow, R., Jursic, B., Yan, Z.F., Friedman, E., Leng, L., Ngo, L., Rifkind, R.A. and Marks, P.A. (1991) Potent cytodifferentiating agents related to hexamethylenebisacetamide. *Proc. Natl. Acad. Sci. USA*, **88**, 5542–5546.

13 Marks, P.A., Rifkind, R.A., Richon, V., Powell, T., Busquets, X., Leng, L., Kiyokawa, H., Michaeli, J., Jursic, B. and Breslow, R. (1992) Hexamethylene bisacetamide and related agents as inducers of differentiation of transformed cells: Mechanism of action and potential for cancer therapy. in *Concise Reviews in Experimental and Clinical Hematology*, (ed. M.J. Murphy), AlphaMed Press, Dayton, pp. 91–99.

14 Richon, V.M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R.A. and Marks, P.A. (1996) Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. *Proc. Natl. Acad. Sci. USA*, **93**, 5705–5708.

15 Richon, V.M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R.A. and Marks, P.A. (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. *Proc. Natl. Acad. Sci. USA*, **95**, 3003–3007.

16 Webb, Y., Ngo, L., Richon, V.M., Breslow, R., Rifkind, R. and Marks, P.A. (1998) Identification of a potential target for hybrid polar cytodifferentiation agents. *Proc. Am. Assoc. Cancer Res.*, **39**, 108.

17 Marks, P.A., Richon, V.M., Breslow, R. and Rifkind, R.A. (1999) Hybrid polar inducers of transformed cell differentiation/apoptosis. From the cell to the clinic. *CR Acad. Sci. Paris/Life Sci.*, **322**, 161–165.

18 Yoshida, M., Kijima, M., Akita, M. and Beppu, T. (1990) Potent and specific inhibition of mammalian histone deacetylase both *in vivo* and *in vitro* by trichostatin A. *J. Biol. Chem.*, **265**, 17174–17179.

19 Webb, Y., Zhou, X., Ngo, L., Cornish, V., Stahl, J., Erdjument-Bromage, H., Tempst, P., Rifkind, R.A., Marks, P.A., Breslow, R. and Richon, V. (1999) Photoaffinity labeling and mass spectrometry identify ribosomal protein S3 as a potential target for hybrid polar cytodifferentiation agents. *J. Biol. Chem.*, **274**, 14280–14287.

20 Finnin, M.S., Donigian, J.R., Cohen, A., Richon, V.M., Rifkind, R.A., Marks, P.A.,

Breslow, R. and Pavletich, N.A. (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. *Nature*, **401**, 188–193.

21 Butler, L.M., Webb, Y., Agus, D.B., Higgins, B., Tolentino, T.R., Kutko, M.C., LaQuaglia, M.P., Drobnjak, M., Cordon-Cardo, C., Scher, H.I., Breslow, R., Richon, V.M., Rifkind, R.A. and Marks, P.A. (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. *Clin. Cancer Res.*, **7**, 962–970.

22 Marks, P.A., Rifkind, R.A., Richon, V.M., Breslow, R., Miller, T. and Kelly, W.K. (2001) Histone deacetylases and cancer: Causes and therapies. *Nat. Rev. Cancer*, **1**, 194–202.

23 Marks, P.A., Rifkind, R.A., Richon, V.M. and Breslow, R. (2001) Inhibitors of histone deacetylase are potentially effective anticancer agents. *Clin. Cancer Res.*, **7**, 759–760.

24 Haggarty S.J., Koeller, K., Grozinger, C.M. and Schreiber, S.L. (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. *Proc. Natl. Acad. Sci. USA*, **100**, 4389–4394.

25 Lee, J.-H., Mahendran, A., Yao, Y., Ngo, L., Venta-Perez, G., Choy, M., Kim, N., Ham, W.-S., Breslow, R. and Marks, P.A. (2013) Development of a histone deacetylase 6 inhibitor and its biological effects. *Proc. Natl. Acad. Sci. USA*, **110**, 15704–15709.

26 Lee, J.-H., Yao, Y., Mahendran, A., Ngo, L., Venta-Perez, G., Choy, M.L., Breslow, R. and Marks, P.A. (2015) Creation of a histone deacetylase 6 inhibitor and its biological effects. *Proc. Natl. Acad. Sci. USA*, **112** (39), 12005–12010

Ronald Breslow is Professor of Biology & Chemistry at Columbia University, one of 12 University Professors and a former Chairman of the Department. Dr Breslow received a BA in chemistry and an MA in medical science before receiving his PhD in chemistry from Harvard under R.B. Woodward. He pursued postdoctoral study at Cambridge University under Lord Todd before joining Columbia. His research accomplishments include synthesis of cyclopropenyl cation (the simplest aromatic system), establishing the concept of antiaromaticity, discovery of the biochemical reaction mechanism of thiamine and synthesis of small molecules that mimic enzymatic reactions as well as the discovery of SAHA and other HDAC inhibitors. Dr Breslow holds memberships in many professional societies such as the US National Academy of Sciences, the American Academy of Arts and Science, the Royal Society of Chemistry of Great Britain and the Chemistry Society of Japan. He has received numerous accolades during his career, including the National Academy of Sciences Award in Chemistry, the US National Medal of Science, the Arthur C. Cope Award and the Priestly Medal.